Mereo BioPharma Group PLC
mereobiopharma.comWhat Do They Do?
Develops drug candidates for rare bone and lung diseases, working with pharmaceutical and biotechnology companies on development and potential commercialization.
10-K for FY2025, filed Mar 19, 2026
How Do They Make Money?
Pharmaceutical and biotechnology partners pay upfront for licenses to develop or commercialize candidates; Mereo may also receive milestone payments when development, regulatory or sales targets are reached, plus royalties on product sales. Upfront license fees arrive when the partner can use the license.
10-K for FY2025, filed Mar 19, 2026The Company’s ongoing major or central operations are the development of product candidates to key clinical milestones and either…View ↗
The terms of these arrangements typically include payment to the Company of one or more of the following: nonrefundable, upfront license…View ↗
If a license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in the…View ↗
$500K
-
10-K for FY2025, filed Mar 19, 2026
$500K ↗
Who Are Their Customers?
Pharmaceutical and biotechnology companies contract with Mereo for licenses and development collaborations, receiving rights that may cover global markets or specified territories.
10-K for FY2025, filed Mar 19, 2026The Company’s ongoing major or central operations are the development of product candidates to key clinical milestones and either…View ↗
The terms of these arrangements typically include payment to the Company of one or more of the following: nonrefundable, upfront license…View ↗
The following table summarizes our pipeline for our core product candidates. We have global commercial rights to alvelestat, commercial…View ↗
Do Revenues Turn Into Profits?
No. It lost $41.9M in FY2025.
10-K for FY2025, filed Mar 19, 2026
−$40.1MView ↗
10-K for FY2025, filed Mar 19, 2026
−$41.9MView ↗
10-K for FY2025, filed Mar 19, 2026
−$31MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$7MView ↗
- ▼ −52% (Loss)
- vs −$14.6M in Q2 FY2025
-
Aug 19, 2026
Nasdaq gave Mereo more time to meet its minimum bid-price rule
Nasdaq granted a second compliance period through February 16, 2027; the notices do not immediately affect the ADS listing.
Sources
8-K, filed Aug 19, 2026
On August 18, 2026, the Company received a second notice (the “Second Notice”) from the Staff indicating that, while the Company has not…View ↗
-
Aug 11, 2026
Mereo granted Sentynl an option for U.S. alvelestat commercial rights
If Sentynl exercises the option, Mereo can receive upfront and research-and-development payments, milestones and royalties on U.S. sales; Mereo will lead the global Phase 3 study.
Sources
8-K, filed Aug 11, 2026
On August 11, 2026, Mereo BioPharma Group plc (the “Company” or "Mereo") entered into an Option and License Agreement (the “Agreement”)…View ↗
Expanded rare-disease pipeline
The older report described setrusumab and alvelestat as its rare-disease candidates; the latest also describes vantictumab, an early-stage program for a second bone disease developed with āshibio.
20-F for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Mar 19, 2026We are a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. We have developed a robust…View ↗
We are a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. We have developed a portfolio…View ↗
Leflutrozole moved to a partner
The older report said Mereo planned to partner or sell leflutrozole; the latest says ReproNovo holds a global license and is responsible for its future research, development and commercialization.
20-F for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Mar 19, 2026We plan to partner or sell our other two product candidates acumapimod for the treatment of AECOPD and leflutrozole for the treatment of…View ↗
Who Do They Compete With?
Competes with Amgen, UCB, Transcenta Holding, Lilly, BOOST Pharma, Angitia Biopharmaceuticals, Grifols, Shire, CSL, Kamada, Sanofi, Wave, Beam, Krystal, Korro, Roche, Merck, iTeos, GSK, and BeOne Medicines
10-K for FY2025, filed Mar 19, 2026We consider setrusumab’s current closest potential competitors in development for the treatment of OI to be Amgen and UCB’s anti-sclerostin…View ↗
Loading...
